Primary Retinal Detachment

More documents

Recommendations

Info

158 7 Pharmacological Approaches to Improve Surgical Outcomes 30. Scott IU, Flynn HW Jr, Murray TG, Feuer WJ (2003) Perfluoron study group. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol 136:454–463 31. Blumenkranz MS, Claflin A, Hajek AS (1984) Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 102:598–604 32. Blumenkranz MS, Hartzer MK, Hajek AS (1987) Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol 105:396–399 33. Williams RG, Chang S, Comaratta M, Simoni G (1996) Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234: 496–503 34. Peyman GA, Cheema R, Conway MD, Fang T (2000) Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 20:554–555 35. Barrada A, Peyman GA, Case J, Fishman G, Thomas A, Fiscella R (1984) Evaluation of intravitreal 5-fluorouracil, vincristine, VP16, doxorubicin, and thiotepa in primate eyes. Ophthalmic Surg 15:767–769 36. Berger AS, Cheng CK, Pearson A, Ashton P, Crooks P, Cynkowski T, Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37:2318– 2325 37. Rubsamen PE, Davis P, Hernandez E, O’Grady G, Cousins SW (1994) Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 112: 407–413 38. Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, and Fisher SK (1983) Ocular toxicity of fluorouracil after vitrectomy.Am J Ophthalmol 96: 43–51 39. Hartzer MK, Blumenkranz MS, Hajek AS, Dailey WD, Cheng M, Margherio AS (1989) Selection of therapeutic agents for the treatment of intraocular proliferative disease. Part 3. Effects of fluoropyrimidines on cell-mediated contraction. Exp Eye Res 48:321–328 40. Berger AS, Cheng CK, Pearson A, Ashton P, Crooks P, Cynkowski T, Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release cortico-
References 159 steroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37:2318–2325 41. Perkins SL, Galemore R, Yang CH, Guo H, Ashton P, Jaffe GJ (2000) Pharmacokinetics of the flucinolone/5-fluorouracil codrug in the gasfilled eye. Retina 20:514–519 42. Asaria RH, Kon CH, Bunce C, Charteris D,Wong D, Khaw P,Aylward G (2001) Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108:1179–1183 43. Wiedemann P, Leinung C, Hilgers RD, Heimann K (1991) Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 229:150–152 44. Campochiaro PA,Hackett SF,Conway BP (1991) Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 32:65–72 45. Mandava N, Blackburn P, Paul D, Wilson M, Read S, Alspaugh E, Tritz R, Barber J, Robbins J, Kruse C (2002) Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 43:3338–3348 46. Van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ (1985) Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 26: 1140–1147 47. Lemor M, Yeo JH, Slater B (1986) Oral colchicine for the treatment of experimental retinal detachment. Arch Ophthalmol 104:1226–1229 48. Blumenkranz M, Hartzer M, Iverson D (1992) An overview of potential applications of heparin in vitreoretinal surgery. Retina 12[Suppl]: S71–S74 49. Bratt G, Tornebohm E, Lockner D, Bergstrom K (1985) A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 53:208–211 50. Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS (1991) Inhibition of intraocular fibrin formation following infusion of lowmolecular weight heparin during vitrectomy.Arch Ophthalmol Vis Sci 109:405–409 51. Chapman C, Iverson D, Hartzer M, Minelli E, and Blumenkranz M (1992) The effect of low molecular weight heparin on proliferative vitreoretinopathy induced in the rabbit eye. Invest Ophthalmol Vis Sci 33[Suppl]:818
Page 2 and 3:
Ingrid Kreissig (Ed.) Primary Retin
Page 4 and 5:
Professor Dr. med. Ingrid Kreissig
Page 6 and 7:
Contents 1 The History of Retinal D
Page 8 and 9:
List of Contributors Gary W. Abrams
Page 10 and 11:
List of Contributors XI Hermann D.
Page 12 and 13:
2 Helmholz in 1850 made an accurate
Page 14 and 15:
4 (vitreous, gelatin) into the ante
Page 16 and 17:
6 with scleral resection that set t
Page 18 and 19:
8 ditis [72-74].Temperatures up to
Page 20 and 21:
10 1 The History of Retinal Detachm
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
16 ion [147]. Perfluorocarbon liqui
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
26 2 Prophylaxis in Fellow Eye of P
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
32 found that eyes with pre-existin
Page 44 and 45:
Page 46 and 47:
36 3 Encircling Operation with Drai
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Chapter 4 Pneumatic Retinopexy for
Page 66 and 67:
Technique 57 Case Selection Proper
Page 68 and 69:
Technique 59 Table 4.1. Gas charact
Page 70 and 71:
Technique 61 solution; however,thes
Page 72 and 73:
Technique 63 gas reflux. Following
Page 74 and 75:
Complications: Prevention and Manag
Page 76 and 77:
New Possibilities 67 ing on type an
Page 78 and 79:
Results 69 Table 4.7 (continued) Au
Page 80 and 81:
Discussion 71 surgical failures. Fa
Page 82 and 83:
Discussion 73 Disadvantages of PR A
Page 84 and 85:
References 75 situations, then to p
Page 86 and 87:
References 77 24. Tornambe PE, Hilt
Page 88 and 89:
References 79 51. Pournaras CJ, Don
Page 90 and 91:
Chapter 5 Vitrectomy for the Primar
Page 92 and 93:
Indications 83 Table 5.1. Indicatio
Page 94 and 95:
Indications 85 Fig. 5.2. The vitreo
Page 96 and 97:
Surgical Technique 87 vitrectomy an
Page 98 and 99:
Outcomes 89 will be visible under a
Page 100 and 101:
Outcomes 91 almost no persistent su
Page 102 and 103:
References 93 7. Heimann H, Bornfel
Page 104 and 105:
96 6 Minimal Segmental Buckling Wit
Page 106 and 107:
98 6 Minimal Segmental Buckling Wit
Page 108 and 109:
100 the operating table with the re
Page 110 and 111:
102 6 Minimal Segmental Buckling Wi
Page 112 and 113:
104 6 Minimal Segmental Buckling Wi
Page 114 and 115:
106 a b 6 Minimal Segmental Bucklin
Page 116 and 117: 108 a b 6 Minimal Segmental Bucklin
Page 118 and 119: 110 6 Minimal Segmental Buckling Wi
Page 122 and 123: 114 a 6 Minimal Segmental Buckling
Page 124 and 125: 116 a b 6 Minimal Segmental Bucklin
Page 130 and 131: 122 c d 6 Minimal Segmental Bucklin
Page 132 and 133: 124 c Fig. 6.14c 6 Minimal Segmenta
Page 134 and 135: Table 6.1. Preoperative characteris
Page 136 and 137: Table 6.3. Final attachment after m
Page 138 and 139: 130 Choroidals In 4 of the 1,462 de
Page 140 and 141: Table 6.4. Visual acuity at 2 years
Page 148 and 149: 140 Probably, the future question n
Page 154 and 155: 146 7 Pharmacological Approaches to
Page 160 and 161: 152 heparin was published in eyes u
Page 162 and 163: 154 search for compounds with hepar
Page 168 and 169: Chapter 8 Systematic Review of Effi
Page 170 and 171: Materials and Methods 163 Table 8.2
Page 172 and 173: Discussion 165 30% 25% 20% 15% 10%
Page 174 and 175: Discussion 167 Fig. 8.2. The small
Page 176 and 177: Conclusion 169 vitrectomy and searc
Page 178 and 179: References 171 8. Brazitikos PD, D
Page 180 and 181: References 173 34. Gunduz K, Gunalp
Page 182 and 183: References 175 63. Schepens CL (195
Page 184 and 185: 178 9 Repair of Primary Retinal Det
Page 186 and 187: 180 a b Fig. 9.3a,b. Legend see pag
Page 192 and 193: 186 a b 9 Repair of Primary Retinal
Page 194 and 195: 188 might eliminate traction on the
Page 198 and 199: Chapter 10 Retinal Detachment Repai
Page 200 and 201: Retinal Detachment Repair: Outlook
Page 212 and 213: References 207 It is impossible to
Page 214 and 215: 210 C Campbell 7 case selection 57,
Page 216 and 217:
212 M Machemer 13 macular - complic
Page 218 and 219:
214 retinal - detachment - - bilate
show all

Primary Retinal Detachment

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?